Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1172 ARTÍCULOS , VIENDO DEL 706 AL 720

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI

Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2011 Jul;32(7):1207-18. doi: 10.1016/j.neurobiolaging.2009.07.002. Epub 2009 Aug 5.

Staged decline of visual processing capacity in mild cognitive impairment and Alzheimer's disease

Bublak P, Redel P, Sorg C, Kurz A, Förstl H, Müller HJ, Schneider WX, Finke K.

Neurobiol Aging. 2011 Jul;32(7):1219-30. doi: 10.1016/j.neurobiolaging.2009.07.012. Epub 2009 Aug 26.

Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype

Kester MI, Verwey NA, van Elk EJ, Blankenstein MA, Scheltens P, van der Flier WM.

Neurobiol Aging. 2011 Aug;32(8):1372-8. doi: 10.1016/j.neurobiolaging.2009.08.006. Epub 2009 Sep 11.

Diffusion tensor imaging and tract-based spatial statistics in Alzheimer's disease and mild cognitive impairment

Liu Y, Spulber G, Lehtimäki KK, Könönen M, Hallikainen I, Gröhn H, Kivipelto M, Hallikainen M, Vanninen R, Soininen H.

Neurobiol Aging. 2011 Sep;32(9):1558-71. doi: 10.1016/j.neurobiolaging.2009.10.006. Epub 2009 Nov 12.

Cathepsin D gene and the risk of Alzheimer's disease: a population-based study and meta-analysis

Schuur M, Ikram MA, van Swieten JC, Isaacs A, Vergeer-Drop JM, Hofman A, Oostra BA, Breteler MM, van Duijn CM.

Neurobiol Aging. 2011 Sep;32(9):1607-14. doi: 10.1016/j.neurobiolaging.2009.10.011. Epub 2009 Nov 18.

The relationship of cardiovascular risk factors to Alzheimer disease in Choctaw Indians

Weiner MF, Hynan LS, Rossetti H, Womack KB, Rosenberg RN, Gong YH, Qu BX.

Am J Geriatr Psychiatry. 2011 May;19(5):423-9. doi: 10.1097/JGP.0b013e3181e89a46.

[The importance of depressive syndromes for incipient Alzheimer-type dementia in advanced age]

Rapp MA, Hellweg R, Heinz A.

Nervenarzt. 2011 Sep;82(9):1140-4. doi: 10.1007/s00115-010-3129-y.

Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: insights into memory loss in MCI

Aluise CD, Robinson RA, Cai J, Pierce WM, Markesbery WR, Butterfield DA.

J Alzheimers Dis. 2011;23(2):257-69. doi: 10.3233/JAD-2010-101083.

The obesity related gene, FTO, interacts with APOE, and is associated with Alzheimer's disease risk: a prospective cohort study

Keller L, Xu W, Wang HX, Winblad B, Fratiglioni L, Graff C.

J Alzheimers Dis. 2011;23(3):461-9. doi: 10.3233/JAD-2010-101068.

Sharing pathogenetic mechanisms between acute myocardial infarction and Alzheimer's disease as shown by partially overlapping of gene variant profiles

Licastro F, Chiappelli M, Caldarera CM, Porcellini E, Carbone I, Caruso C, Lio D, Corder EH.

J Alzheimers Dis. 2011;23(3):421-31. doi: 10.3233/JAD-2010-090871.

Potential predictors of hippocampal atrophy in Alzheimer's disease

Dhikav V, Anand K.

Drugs Aging. 2011 Jan 1;28(1):1-11. doi: 10.2165/11586390-000000000-00000.

Scientific truth or false hope? Understanding Alzheimer's disease from an aging perspective

Chen M, Maleski JJ, Sawmiller DR.

J Alzheimers Dis. 2011;24(1):3-10. doi: 10.3233/JAD-2010-101638.

Association between bone mineral density and the risk of Alzheimer's disease

Zhou R, Deng J, Zhang M, Zhou HD, Wang YJ.

J Alzheimers Dis. 2011;24(1):101-8. doi: 10.3233/JAD-2010-101467.

Neurogenesis, NSCs, pathogenesis and therapies for Alzheimer's disease

Taupin P.

Front Biosci (Schol Ed). 2011 Jan 1;3(1):178-90. doi: 10.2741/s143.

Inflammation and oxidative damage in Alzheimer's disease: friend or foe?

Galimberti D, Scarpini E.

Front Biosci (Schol Ed). 2011 Jan 1;3(1):252-66. doi: 10.2741/s149.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias